Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Bully Pulpit: Trump Versus Drug Prices

Executive Summary

Medicare price negotiation is not a new idea – nor is the concept of using the Presidential megaphone to talk down drug prices. Will Trump and Twitter turn it into something bigger?

You may also be interested in...



Dems' 'Better Deal' Would Create Drug Price Gouging 'Enforcer'

Plan would empower new agency to investigate and potentially fine drug manufacturers that make unjustified price increases.

NIH Director Collins Stays On: Continuity For ‘Moonshot’ – And Barrier To ‘March In’

For industry, the sole health agency head held over from the Obama Administration means the ‘Moonshot’ priorities will move forward – and one possible threat to pricing is cut off.

Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?

President-elect threatens a government bidding process to control drug pricing in his first post-election press conference.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119853

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel